TURBT术后即刻膀胱灌注不同浓度吡柔比星对浅表性膀胱癌患者免疫功能及生活质量的影响

目的:研究经尿道膀胱肿瘤电切术(TURBT)术后即刻膀胱灌注不同浓度吡柔比星对浅表性膀胱癌(SBC)患者免疫功能及生活质量的影响。方法:选择从2015年6月到2018年6月在我院治疗的SBC患者126例作为此次研究对象。依据随机数字法将患者分成观察组以及对照组,每组各63例,两组患者均常规给予TURBT治疗,手术完成后即刻,观察组患者采用30 mg的吡柔比星~+30 m L浓度为5%的葡萄糖液行胱灌注化疗,对照组采用30 mg的吡柔比星~+50 m L浓度为5%的葡萄糖液行胱灌注化疗。治疗1年后对比两组复发情况、免疫功能指标、生活质量以及不良反应。结果:观察组的复发率明显低于对照组,且复发时间明显长于对照组,差异均有统计学意义(P0.05)。两组治疗后的CD3~+、CD4~+、CD8~+水平及生活质量各方面评分均明显高于治疗前,差异有统计学意义(P0.05);两组治疗前及治疗后的CD3~+、CD4~+、CD8~+水平及生活质量各方面评分相比差异无统计学意义(P0.05)。观察组各种不良反应及其总发生率与对照组相比差异无统计学意义(P0.05)。结论:SBC患者在TURBT术后即刻实施吡柔比星膀胱灌注能够提升其免疫功能及生活质量,但30 mg的吡柔比星~+30 m L浓度为5%的葡萄糖液的膀胱灌注用药方案能够获得更低的术后复发率,复发时间也随之延长。

Effect of Immediate Intravesical Instillation of Different Concentration of Pipirubicin on Immune Function and Quality of Life in Patients with Superficial Bladder Cancer after TURBT

ABSTRACT Objective: To study the effect of immediate intravesical instillation of different concentration of pipirubicin on immune function and quality of life in patients with superficial bladder cancer (SBC) after transurethral resection of bladder tumor (TURBT). Methods: 126 patients with SBC who were treated in our hospital from June 2015 to June 2018 were selected as the object of the study. According to the random number method, the patients were divided into the observation group and the control group with 63 cases in each group. The two groups were routinely treated with TURBT. Immediately after operation, the patients in the observation group were given infusion chemotherapy with 30 mg''s pirarubicin and 30 mL of 5% of the glucose solution, and the patients in the control group were given infusion chemotherapy with 30 mg''s pirarubicin and 50 mL of 5% of the glucose solution. 1 years after treatment, the recurrence, immune function, quality of life and adverse reactions were compared between the two groups. Results: The recurrence rate of the observation group was significantly lower than the control group, and the recurrence time was significantly longer than that of the control group (P<0.05). The levels of CD3⁺, CD4⁺, CD8⁺ and the scores of quality of life in the two groups were significantly higher than those before treatment, and the difference was statistically significant (P<0.05). There was no significant difference in the levels of CD3⁺, CD4⁺, CD8⁺ and the scores of quality of life between the two groups before and after treatment (P>0.05). There was no significant difference in the adverse reactions and the total incidence of the observation group compared with the control group (P>0.05). Conclusion: Immediate intravesical instillation of pirarubicin can improve the immune function and quality of life in patients with SBC after TURBT. However, intravesical instillation of 30 mg''s pirarubicin and 30 mL of 5% of the glucose solution can achieve lower postoperative recurrence rate, the recurrence time is also prolonged.